The landscape of biomedical research is undergoing a profound transformation, driven by advancements in single-cell transcriptomics. This powerful technology, which dissects gene expression at the individual cell level, offers unprecedented insights into cellular heterogeneity, a critical factor in understanding complex biological processes and diseases. However, the widespread adoption of single-cell transcriptomics has been hampered by the laborious and time-consuming nature of its workflows. To address these challenges, a growing emphasis on automation is emerging, promising to enhance efficiency, accessibility, and reproducibility. Kelly Parliament, Staff Application Scientist at Beckman Coulter Life Sciences, is at the forefront of this movement, discussing how automation is revolutionizing single-cell transcriptomic workflows and paving the way for accelerated discoveries in areas such as cancer research, immunology, and cell and gene therapy.
The Evolution and Significance of Single-Cell Transcriptomics
Historically, gene expression analysis relied on bulk RNA sequencing, which provides an average of gene activity across a population of cells. While valuable, this approach can mask crucial variations that exist between individual cells within a tissue or sample. Single-cell transcriptomics circumvents this limitation by analyzing the transcriptome of each cell separately. This granular resolution allows researchers to identify distinct cell types, pinpoint rare cell populations, understand cellular responses to stimuli, and unravel the intricate mechanisms underlying disease development and progression. The ability to discern these subtle differences is a significant leap forward from traditional methods, offering a more nuanced and accurate representation of biological systems.
The growing appreciation for the power of single-cell transcriptomics has led to a surge in its application across diverse fields. In oncology, researchers are using it to identify specific cancer cell subtypes that may be resistant to therapy, paving the way for more targeted treatments. In immunology, it’s instrumental in dissecting the complex interactions between immune cells and their environment, crucial for developing effective immunotherapies and vaccines. Furthermore, the burgeoning field of cell and gene therapy (CGT) relies heavily on single-cell analysis to characterize therapeutic cells, monitor their efficacy, and understand potential off-target effects. The potential impact on drug discovery and development is equally profound, enabling a deeper understanding of how novel therapeutics interact with the vast array of cell types in the body.
Challenges in Scaling Single-Cell Workflows
Despite its immense promise, the practical implementation of single-cell transcriptomics faces significant hurdles, primarily related to workflow efficiency and scalability. Traditional single-cell protocols are characterized by intricate manual steps, demanding high levels of precision and often requiring specialized expertise. These manual processes are not only time-consuming but also prone to human error, leading to variability in results and increasing the cost and complexity of experiments.
A critical bottleneck in these workflows is library preparation, a multi-step process that involves isolating RNA, reverse transcribing it into cDNA, and then amplifying and barcoding these molecules for sequencing. Each of these steps requires careful handling of sensitive reagents and precise pipetting, often under controlled temperature conditions. For a researcher working manually, processing more than 24 samples per day is often an insurmountable challenge. This limitation significantly impedes the throughput of studies requiring large sample sizes, such as those investigating disease heterogeneity across patient cohorts or screening numerous drug candidates. The extended turnaround times associated with manual processing can delay critical research timelines and slow down the pace of innovation.
The imperative for industry stakeholders, including technology developers and contract research organizations (CROs), is clear: to develop and implement scalable, high-throughput solutions that streamline these complex workflows. This necessitates a focus on automation, which has the potential to significantly reduce hands-on time, minimize errors, and accelerate the entire process from sample preparation to data analysis.
Beckman Coulter Life Sciences and 10x Genomics: A Collaborative Approach to Automation
Recognizing the urgent need to overcome these limitations, Beckman Coulter Life Sciences has embarked on a strategic collaboration with 10x Genomics, a leader in single-cell analysis technologies. This partnership, initiated in 2023, is dedicated to automating critical aspects of single-cell gene expression workflows. The core objective is to translate the precision and consistency of manual methods into automated platforms, ensuring that efficiency gains do not come at the expense of data quality.
The collaboration leverages the strengths of both companies. Beckman Coulter Life Sciences brings its expertise in laboratory automation, including liquid handling and workflow management systems. 10x Genomics contributes its innovative single-cell technologies, such as the Chromium platform, which is widely adopted for generating high-quality single-cell libraries. Together, they aim to create integrated solutions that simplify the entire single-cell workflow, making it more accessible and efficient for a broader range of researchers.
A Case Study: Single Cell Discoveries (SCD) B.V. and Automated Library Preparation
The impact of this collaborative effort is vividly illustrated by the experience of Single Cell Discoveries (SCD) B.V., a prominent CRO specializing in single-cell sequencing services. As SCD’s customer base expanded and the demand for larger-scale projects grew, the organization faced the challenge of increasing its sample processing capacity beyond the limitations of manual workflows. Their goal was to process up to 96 samples per day while maintaining a robust turnaround time of four to six weeks, a critical factor for their clients in drug development and clinical research.
To achieve this ambitious objective, SCD partnered with Beckman Coulter Life Sciences and 10x Genomics to implement an automated library preparation solution. This involved integrating Beckman Coulter’s flexible liquid handling platforms with 10x Genomics’ single-cell technologies. The chosen system offers advanced features, including multi-channel pipetting heads and Span-8 pipetting capabilities, allowing for precise liquid transfers across a variety of labware and dispensing volumes. This flexibility is crucial for optimizing reagent usage and adapting to different experimental designs.
A key component of the automated solution is an integrated cooling system that maintains the stable temperatures required for sensitive enzymatic reactions during library preparation. This ensures the consistency and reliability of the process, which are paramount for generating high-quality data. The ability to automate these precise manual steps not only addresses the throughput challenge but also significantly reduces the potential for human error.
Michiel Fokkelman, PhD, Automation Scientist at SCD, highlighted the transformative impact of this automation in a webinar in May 2025. He reported that SCD has tripled its sample processing capacity, moving from the manual throughput of 24 samples per day to an automated capacity of up to 96 samples per day. Crucially, this increase in throughput has been accompanied by a dramatic reduction in hands-on time for lab scientists. What previously required over five hours of manual work per day has now been reduced to approximately one hour. This substantial freeing up of researcher time allows them to focus on more analytical and interpretative tasks, accelerating the overall research cycle.
Furthermore, Fokkelman emphasized the significant reduction in data variability observed with the automated workflow. "Robots typically don’t make pipetting mistakes, whereas a human, of course, could potentially make mistakes," he stated. This leads to enhanced standardization and greater consistency in the final sequencing product, ultimately improving the reliability and reproducibility of research findings.
The Expanding Horizon of Automation in Single-Cell Research
The integration of automation in single-cell transcriptomics is not limited to library preparation. The industry is actively pursuing the automation of other crucial steps within the workflow. These include cDNA synthesis, a vital step in converting RNA into a format suitable for sequencing, and cell-surface protein assays, which provide complementary information about cell identity and function.
Another rapidly advancing area is Variable Diversity Joining (VDJ) profiling, a specialized form of single-cell transcriptomics that focuses on analyzing the immune repertoire of T and B cells. Automating these VDJ profiling workflows is expected to further enhance traceability and consistency across large sample sets, reducing the need for researchers to repeatedly perform experiments to validate their findings.
The implications of this ongoing automation are far-reaching and directly translate to improved patient outcomes. By enabling a deeper understanding of T and B cell activity at the single-cell level, researchers can develop more effective immunotherapies for a range of diseases, including cancer. In the realm of drug development, single-cell transcriptomics, empowered by automation, is unveiling intricate details about how medicines affect the diverse cellular landscape of the body. This provides invaluable insights into the mechanisms of action of drugs, identifies potential side effects earlier in the development process, and allows for the optimization of therapeutic strategies.
The Future Trajectory: From Niche to Mainstream
The trajectory of single-cell transcriptomics, fueled by automation, mirrors the evolution of next-generation sequencing (NGS). NGS initially emerged as a specialized technology confined to well-equipped research institutions. However, with advancements in instrumentation, chemistry, and bioinformatics, it has become an indispensable tool across virtually all areas of life sciences. Similarly, single-cell transcriptomics is rapidly transitioning from a specialized technique to a mainstream technology, becoming an invaluable asset for understanding the complexity of human cells.
This progression is being propelled by ongoing collaborations between CROs, technology developers, and biopharmaceutical innovators. These partnerships are essential for driving the development and adoption of robust, scalable, and user-friendly single-cell solutions. As automation continues to mature and become more integrated into these workflows, researchers will be empowered to ask more complex biological questions and obtain clearer, more reproducible answers than ever before. The ability to dissect biological systems at the single-cell level with unprecedented efficiency and accuracy promises to unlock new frontiers in medicine and accelerate the discovery of novel diagnostics and therapeutics. The era of deeply understanding cellular individuality has truly begun, and automation is the key to unlocking its full potential.
Leave a Reply